ZEVRA THERAPEUTICS, INC. (ZVRA) is a publicly traded company in the Unknown sector. Across all available filings, 13 corporate insiders have executed 33 transactions totaling $895.0K, demonstrating a bullish sentiment with $473.0K in net insider flow. The most recent transaction on Oct 10, 2025 involved a sale of 19,500 shares valued at $211.0K.
No significant insider buying has been recorded for ZVRA in the recent period.
No significant insider selling has been recorded for ZVRA in the recent period.
Based on recent SEC filings, insider sentiment for ZVRA is bullish with an Insider Alignment Score of 76/100 and a net flow of $473.0K. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at ZEVRA THERAPEUTICS, INC. (ZVRA) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 13 insiders are actively trading ZVRA stock, having executed 33 transactions in the past 90 days. The most active insider is Neil F. Mcfarlane (Executive), who has made 2 transactions totaling $211.0K.
Get notified when executives and directors at ZVRA file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Oct 10, 2025 | F. Mcfarlane Neil | Executive | Sale | 19,500 | $10.82 | $211.0K | |
| Oct 10, 2025 | F. Mcfarlane Neil | Executive | Option Exercise | 50,000 | $N/A | $0 | |
| Sep 12, 2025 | Shih Alvin | Executive | Purchase | 20,000 | $7.89 | $157.8K | |
| Sep 12, 2025 | A. Favorito Tamara | Executive | Purchase | 3,175 | $7.79 | $24.7K | |
| Aug 19, 2025 | B. Bode John | Executive | Purchase | 5,000 | $9.17 | $45.9K | |
| Jul 17, 2024 | Laduane Clifton R. | Executive | Purchase | 2,000 | $6.77 | $13.5K | |
| Jul 16, 2024 | Anderson Thomas | Executive | Purchase | 10,000 | $6.81 | $68.1K | |
| Jul 12, 2024 | B. Bode John | Executive | Purchase | 10,000 | $5.87 | $58.7K | |
| Sep 6, 2023 | Anderson Thomas | Executive | Purchase | 10,000 | $4.88 | $48.8K | |
| Sep 6, 2023 | Laduane Clifton R. | Executive | Purchase | 1,000 | $4.96 | $5.0K | |
| Sep 5, 2023 | B. Bode John | Executive | Purchase | 10,000 | $5.13 | $51.3K | |
| Sep 5, 2023 | Schafer Joshua | Executive | Purchase | 500 | $5.13 | $2.6K | |
| Jun 23, 2023 | Michael Watton Corey | Executive | Purchase | 275 | $5.95 | $1.6K | |
| Jun 9, 2023 | Michael Watton Corey | Executive | Purchase | 325 | $5.52 | $1.8K | |
| May 30, 2023 | Michael Watton Corey | Executive | Purchase | 400 | $5.11 | $2.0K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Purchase(P) | 31 | $684.0K | 76.4% |
Sale(S) | 1 | $211.0K | 23.6% |
Exercise(M) | 1 | $0 | 0.0% |
Insiders at ZEVRA THERAPEUTICS, INC. are accumulating shares at an accelerated pace. With 13 insiders making 33 transactions totaling $684.0K in purchases versus $211.0K in sales, the net buying activity of $473.0K signals strong executive confidence. Neil F. Mcfarlane (Executive) leads the buying activity with $211.0K in transactions across all time.